Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesShort-Term Debt repaymentsWages, Salaries and Other
Ratios

Nutex Health (NUTX) Accumulated Depreciation & Amortization (2016 - 2026)

Nutex Health (NUTX) has disclosed Accumulated Depreciation & Amortization for 9 consecutive years, with $5.5 million as the latest value for Q1 2026.

  • For Q1 2026, Accumulated Depreciation & Amortization rose 7.86% year-over-year to $5.5 million; the TTM value through Mar 2026 reached $5.5 million, up 7.86%, while the annual FY2025 figure was $20.5 million, 8.21% up from the prior year.
  • Accumulated Depreciation & Amortization hit $5.5 million in Q1 2026 for Nutex Health, down from $20.5 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $82.4 million in Q1 2023 and bottomed at $4.2 million in Q1 2024.
  • Average Accumulated Depreciation & Amortization over 5 years is $19.5 million, with a median of $13.4 million recorded in 2022.
  • Year-over-year, Accumulated Depreciation & Amortization soared 34.21% in 2023 and then tumbled 94.92% in 2024.
  • Nutex Health's Accumulated Depreciation & Amortization stood at $13.1 million in 2022, then surged by 33.97% to $17.6 million in 2023, then increased by 7.84% to $19.0 million in 2024, then increased by 8.21% to $20.5 million in 2025, then crashed by 73.25% to $5.5 million in 2026.
  • According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods came in at $5.5 million, $20.5 million, and $5.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.